Pharmacotherapeutic group: Other anti-inflammatory and anti-rheumatic agents, non steroids. ATC code: M01AX26.
Pharmacology: Pharmacodynamics: PIASCLEDINE belongs to the new class of "SYSADOA" (symptomatic slow-acting drugs in osteoarthritis), which are notably characterized by their delayed action. For this reason, it may be necessary to prescribe, at the beginning of treatment with PIASCLEDINE, a combined NSAID and/or analgesics, the dosage of which being likely to be reduced, as the PIASCLEDINE efficacy is increasing. Clinical studies have shown that there was a significant carry-over effect of an additional 2 months after the discontinuation of PIASCLEDINE at 6 months. The mode of action of Avocado/Soya Unsaponifiables (ASU) has been assessed through in vitro and in vivo studies in osteoarthritis (OA) which evidenced the following main pharmacological properties. The main targets of the PIASCLEDINE mechanism of action include: An increase in the proteoglycans (PG) synthesis, especially those of high molecular weight, with a quality similar to the nature PG.
A complementary effect of the two components of Piascledine: acute inhibition of PG degradation and chronic stimulation of PG synthesis.
A stimulation of collagen synthesis by synoviocytes and articular chondrocytes. The effects on collagen are supported by a decrease in the IL-1 inhibitory effect and in the synthesis of PGE2 by chondrocytes.
Piascledine also inhibits articular type II collagenase.
Finally, Piascledine was shown to stimulate the expression of TGFβ1 and TGFβ2 and plasminogen activator inhibitor 1 (PAI-1), these effects accounting for a potential beneficial effect on the repair and protection of the extracellular matrix components.
Pharmacokinetics: No assay method, specific and precise enough for pharmacokinetic studies, was available for assay of ASU in biological fluids. Therefore, no data is available about PIASCLEDINE pharmacokinetics.